FDA initiatives to support dose optimization in oncology drug development: the less may be the better
- PMID: 35800667
- PMCID: PMC9253446
- DOI: 10.12793/tcp.2022.30.e9
FDA initiatives to support dose optimization in oncology drug development: the less may be the better
Conflict of interest statement
Conflict of Interest: - Author: Nothing to declare - Reviewers: Nothing to declare - Editors: Nothing to declare
References
-
- Ratain MJ, Tannock IF, Lichter AS. Dose optimization of Sotorasib: is the US Food and Drug Administration sending a message? J Clin Oncol. 2021;39:3423–3426. - PubMed
-
- US Food and Drug Administration. FDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy [Internet] [Accessed May 28, 2021]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-t... .
-
- Optimizing dosing in oncology drug development. Friends of Cancer Research Annual Meeting 2021 [Internet] [Accessed 2021]. https://friendsofcancerresearch.org/publications/
LinkOut - more resources
Full Text Sources